Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 600 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 400 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 300 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 200 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 100 míkróg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - natríum ertapenem - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - sýklalyf fyrir almenn nota, - treatmenttreatment eftirfarandi sýkingum þegar völdum bakteríur þekkt eða mjög líklegt að vera næmir ertapenem og þegar æð meðferð er krafist:kviðarholi sýkingum;samfélag keypti lungnabólgu;bráð móðurlífi sýkingum;sykursýki fæti sýkingar í húð og mjúkur vefjum. preventioninvanz er ætlað í fullorðnir til að fyrirbyggja skurðaðgerð síðuna sýkingu eftir val og skurðaðgerð. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemophilia a - antihemorrhagics - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra hægt er að nota í öllum aldri tekur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - bóluefni - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.